FindMyKOL
Clinical trialNCT01484093CompletedPhase 1/2Interventional

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

NCT01484093 is a phase 1/2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. As of 21 Nov 2026, it is completed. It studies Mantle Cell Lymphoma. The registry lists an enrollment of 96 participants at 5 sites in 1 country. The registry lists a start date of 29 Nov 2011 and a primary completion date of 11 Aug 2023. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01484093
FieldValue
Registry IDNCT01484093
StatusCompleted
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorMemorial Sloan Kettering Cancer Center
Enrollment96
Registered sites5
Countries1
ConditionsMantle Cell Lymphoma
Start29 Nov 2011
Primary completion11 Aug 2023
Study completion11 Aug 2023
Last update posted16 Aug 2023

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Mantle cell lymphoma (MCL) is a rare and aggressive type of lymphoma, with only about 3,000 cases diagnosed per year. MCL is considered a difficult cancer to treat. This study is being done to better understand how to treat MCL.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New Jersey, United States1 site
  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge

New York, United States4 sites
  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack

  • Memorial Sloan Kettering Cancer Center

    New York

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre

  • Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

    Sleepy Hollow

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 4 sitesNY4MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew Jersey: 1 siteNJ1ConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT01484093

Each answer restates registry values shown on this page.

What is NCT01484093?

NCT01484093 is a phase 1/2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. It studies Mantle Cell Lymphoma.

Who leads NCT01484093?

The registry names Andrew Zelenetz, MD,PhD (principal investigator, Memorial Sloan Kettering Cancer Center) as the overall official.

Where does NCT01484093 run?

The registry lists 5 sites in 1 country. Every site with a stated country is in one country: United States.

When did NCT01484093 end?

The registry lists a primary completion date of 11 Aug 2023 and a study completion date of 11 Aug 2023. The sponsor last updated the record on 16 Aug 2023.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.